Prothena Corp PLC (NAS:PRTA)
$ 20.08 -0.96 (-4.56%) Market Cap: 1.08 Bil Enterprise Value: 597.61 Mil PE Ratio: 0 PB Ratio: 2.15 GF Score: 66/100

Prothena Corporation PLC at Barclays Global Healthcare Conference Transcript

Mar 12, 2019 / 12:30PM GMT
Release Date Price: $13.56 (+3.43%)
Gregory Allen Harrison
Barclays Bank PLC, Research Division - Research Analyst

Okay. Today we're lucky enough to have Prothena with us. We have Gene Kinney, CEO; and Tran Nguyen, CFO. My name is Greg Harrison. I'm an associate on Geoff Meacham's team, and with me is Scott Puckhaber.

Questions & Answers

Gregory Allen Harrison
Barclays Bank PLC, Research Division - Research Analyst

So I guess we'll just get right into it, maybe start off with the prasinezumab program in Parkinson's. So you recently published the Phase 1b data. Just curious, we saw a good PK/PD profile. What, beyond that, did you guys find especially meaningful as you progressed this program?

Gene G. Kinney
Prothena Corporation plc - President, CEO & Director

Yes, I know. Well, first, Greg and Scott, thank you for having us. We very much appreciate being here. Yes, just to speak a little bit about prasinezumab. Maybe I can kind of introduce a little bit of science behind it, then we can talk about this Phase 1b results. So that's a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot